首页> 外文OA文献 >A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

【2h】

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

机译：二氮豆种的1次剂量升级研究与利妥昔单抗，环磷酰胺，多柔比星，改性的长春序和未处理滤泡性淋巴瘤和其他低级B细胞淋巴瘤的泼尼松和泼尼松

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rajni Sinha; Jonathan L. Kaufman; Hanna Jean Khoury; Nassoma King; Pareen J. Shenoy; Carol Lewis; Kevin Bumpers; Amanda Hutchison-Rzepka; Mourad Tighiouart; Leonard T. Heffner; Mary Jo Lechowicz; Sagar Lonial; Christopher R. Flowers;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas [J] . SinhaR., KaufmanJ.L., KhouryJr.H.J., Cancer: A Journal of the American Cancer Society . 2012,第14期

机译：硼替佐米联合利妥昔单抗，环磷酰胺，阿霉素，改良长春新碱和泼尼松治疗未经治疗的滤泡性淋巴瘤和其他低度B细胞淋巴瘤的1期剂量递增研究
2. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [J] . Robak Tadeusz, Jin Jie, Pylypenko Halyna, The lancet oncology . 2018,第11期

机译：前线Bortezomib，Rituximab，环磷酰胺，多柔比星和泼尼松（VR-Cap）与rituximab，环磷酰胺，多柔比星，血管内，indnisone（R-Chec）在移植型术术患者淋巴瘤患者中进行移植术语：最终整体生存结果随机，开放标签，第3阶段研究
3. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). [J] . Ribrag V, Gisselbrecht C, Haioun C Cancer: A Journal of the American Cancer Society . 2009,第19期

机译：两种方案的一线利妥昔单抗联合环磷酰胺，阿霉素，长春新碱和泼尼松联合硼替佐米在B细胞淋巴瘤患者中的疗效和毒性：来自法国成人淋巴瘤研究小组（GELA）的一项随机2期试验。
4. DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CANINE LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED STUDY [C] . Janet Lori, Timothy Stein, Douglas Thamm Annual Conference of the Veterinary Cancer Society . 2009

机译：多柔比星和环磷酰胺治疗犬淋巴瘤：随机，安慰剂对照研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Study of Bortezomib Added to Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients with Previously Untreated Indolent non-Hodgkin’s Lymphoma [O] . Jonathon B. Cohen, Jeffrey M. Switchenko, Jean L. Koff, -1

机译：硼替佐米联合利妥昔单抗环磷酰胺阿霉素长春新碱和泼尼松治疗之前未经治疗的惰性非霍奇金淋巴瘤患者的II期研究
7. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione Italiana Linfomi. [O] . Chiappella A, Tucci A, Castellino A, 2013

机译：来那度胺加环磷酰胺，阿霉素，长春新碱，泼尼松和利妥昔单抗在未经治疗的老年弥漫性大B细胞淋巴瘤患者中是安全有效的：Fondazione Italiana Linfomi进行的第一阶段研究。

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

著录项

相似文献

相关主题

期刊订阅